ERBB2 and breast carcinoma: In accord with the results from TCGA database (Fig. 1c), patients of miR-3613-3p low-expression from breast cancer tissue array accounted for a larger proportion in patients with negative clinical marker (ER, HER2 or PR) accordingly compared to patients with positive clinical marker (Fig. 2c).